-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, SS0Xf5jFOowGKpYUf3k5l1JE0WMHRHltoNnBejii3sDV3YhtUaBQVbwIkC17cUCE ws1Q+VedNdOtEanZO+cxKQ== 0001010412-02-000254.txt : 20021113 0001010412-02-000254.hdr.sgml : 20021113 20021113152921 ACCESSION NUMBER: 0001010412-02-000254 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20020409 ITEM INFORMATION: Changes in control of registrant ITEM INFORMATION: Acquisition or disposition of assets ITEM INFORMATION: Other events ITEM INFORMATION: Resignations of registrant's directors ITEM INFORMATION: Financial statements and exhibits ITEM INFORMATION: FILED AS OF DATE: 20021113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: FIRST DELTAVISION INC CENTRAL INDEX KEY: 0001051488 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS ELECTRICAL MACHINERY, EQUIPMENT & SUPPLIES [3690] IRS NUMBER: 870412182 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-23511 FILM NUMBER: 02819827 BUSINESS ADDRESS: STREET 1: 9005 COBBLE CANYON LANE CITY: SANDY STATE: UT ZIP: 84093 BUSINESS PHONE: 8019420555 MAIL ADDRESS: STREET 1: 9005 COBBLE LANE CITY: SANDY STATE: UT ZIP: 84093 8-K/A 1 k8a.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-KA CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act April 9, 2002 ------------- Date of Report (Date of earliest event reported) FIRST DELTAVISION, INC. ----------------------- (Exact name of registrant as specified in its charter) NEVADA 0-23511 87-0412182 ------ ------- ---------- (State or other (Commission File Number) (IRS Employer jurisdiction of Identification incorporation) No.) 9005 Cobble Canyon Lane Salt Lake City, Utah 84093 -------------------------- (Address of Principal Executive Offices) (801) 942-0555 -------------- (Registrant's Telephone Number) 2914 South Sheridan Way, Suite 300 Oakville, Ontario, Canada L6J 7J8 --------------------------------- (Former Name or Former Address if changed Since Last Report) Item 1. Changes in Control of Registrant. --------------------------------- (a) Following a 300% dividend on April 4, 2002, of our outstanding securities, that was accounted for as a four for one forward split, and effective as of April 9, 2002, the Registrant ("First Deltavision," "we," "our" and "us" and words of similar import); Kyomedix Corporation, a Delaware corporation ("Kyomedix"), and Atlantic Capital Partners Inc. and Health Sciences International Inc., shareholders of Kyomedix (the "Kyomedix Stockholders"), executed a Share Exchange Agreement (the "KyoMedix Agreement"), whereby 100% of the issued and outstanding shares of common stock of KyoMedix were converted into and exchanged for 15,166,550 post-dividend shares of our common stock or approximately 96% of our post-KyoMedix Agreement outstanding securities, taking into account the cancellation of 186,648 pre- dividend shares of our common stock that were owned by David C. Merrell. Mr. Merrell was our President and one of our directors prior to the KyoMedix Agreement. The combination of these entities was treated as a purchase for accounting purposes, with KyoMedix becoming our wholly-owned subsidiary on closing. The principal terms of the KyoMedix Agreement were: 1. Prior to the completion of the KyoMedix Agreement, we were required to effect a four for one dividend on outstanding common stock, and 186,648 shares of our pre-dividend shares that were owned by David C. Merrell were required to be delivered for cancellation pending the closing of the KyoMedix Agreement; 2. The issuance of 15,166,550 of our post-dividend shares of common stock ("restricted securities") in exchange for 100% of the outstanding shares of KyoMedix. The 15,166,550 shares represented approximately 96% of our post-KyoMedix Agreement outstanding securities, taking into consideration the cancellation of the 186,648 pre-dividend shares of common stock that were owned by Mr. Merrell. 3. Our adoption of the KyoMedix Employee Stock Option Plan and subject to the written consent of any employee of KyoMedix that had been granted any option thereunder, that such options be exchanged for like options to acquire post-dividend shares of our common stock that are "restricted securities" unless and until the options and the underlying shares were registered with the Securities and Exchange Commission on Form S-8. 4. Following the closing of the KyoMedix Agreement, we were to provide our stockholders with a proxy or information statement to consider and act upon an amendment to our Articles of Incorporation to change our name to "KyoMedix, Inc." and in the interim, we filed a dba in the State of Nevada to conduct business under that name and obtained a new Cusip Number and OTC Bulletin Board Symbol for such name. 5. The designation of the directors and executive officers nominated by the KyoMedix Stockholders as our new directors and executive officers, with our pre-KyoMedix Agreement directors and executive officers resigning, in seriatim. 6. We were required to and did execute and deliver a Promissory Note in the amount of $250,000 payable to David C. Merrell with 90 days of the closing of the KyoMedix Agreement, the payment of which was secured by the pledge of all of the securities of Atlantic Capital Partners Inc. and all but 1,280,000 of the shares of Health Science International Inc. that were received by these KyoMedix Stockholders under the KyoMedix Agreement. Prior to the completion of the KyoMedix Agreement, taking into account the cancellation of the 186,648 pre-dividend shares owned by Mr. Merrell, there were 595,408 outstanding shares of our common stock. Following the completion of the KyoMedix Agreement, there were 15,761,958 post-dividend outstanding shares of our common stock. A copy of the KyoMedix Agreement, including all material exhibits and related instruments, accompanied our initial 8-K Current Report dated April 9, 2002, which is incorporated herein by reference; the foregoing summary of the KyoMedix Agreement is modified in its entirety by reference to such Report. See Item 7. Effective November 11, 2002, the KyoMedix Agreement was rescinded and declared null and void by the parties pursuant to a Compromise and Settlement Agreement, a copy of which is attached hereto and incorporated by reference. See Item 7. Pursuant to the terms and provisions of the Compromise and Settlement Agreement, the parties agreed as follows: 1. The KyoMedix Agreement was rescinded, and the 15,166,550 shares of our common stock that were issued pursuant to the KyoMedix Agreement were canceled. 2. The four for one dividend on our pre-KyoMedix Agreement outstanding securities was retained. 3. The 186,648 pre-KyoMedix Agreement shares of our common stock that were owned by David C. Merrell and that were canceled, were re-issued, and the four for one dividend was effected on these shares; the Promissory Note in the amount of $250,000 payable to Mr. Merrell for his indemnification of us from and against certain liabilities was declared null and void, along with Mr. Merrell's Limited Indemnity Agreement. 4. Our adoption of the KyoMedix Employee Stock Option Plan was declared void. 5. The Certificate of Business: Fictitious Firm Name, which we filed in the State of Nevada under the name "KyoMedix, Inc.." was canceled. 6. Certain Share Purchase Option Agreements, pursuant to which certain shareholders of our stockholders granted certain associates of the KyoMedix Stockholders options that acquire a portion of their shares of common stock, were declared null and void. 7. KyoMedix and the KyoMedix Shareholders agreed to indemnify and hold us harmless from and against any and all liabilities that we may have incurred since April 9, 2002, to the effective date of the Compromise and Settlement Agreement, or while they or their nominees were under our control. 8. The persons who were then serving as our directors or executive officers had their elections and designations as directors and executive officers declared void, and our former directors and executive officers, David C. Merrell and Todd D. Ross, were re-elected as our directors and executive officers for the remainder of their respective terms or until their successors are elected and qualified. 9. All claims of any party against any other party were compromised and settled. 10. The civil action filed by David C. Merrell against all of the parties to the KyoMedix Agreement that was filed in the Third Judicial District Court in Salt Lake County, Utah, filed as Civil Action No. 020910071, a copy of which is attached hereto and incorporated by reference, was dismissed, with prejudice. See Item 7. 11. If any party to the Compromise and Settlement Agreement defaults on any of the terms and provisions hereof, the non-defaulting party or parties shall be entitled to recover reasonable attorney's fees and costs; and any action brought to enforce the terms and provisions of the Compromise and Settlement Agreement must be brought in the State of Nevada and each party consented to such jurisdiction. Each party also agreed to bear its respective costs of the negotiation, consummation and execution of the Compromise and Settlement Agreement and all related matters. (b) To the knowledge of our management and based upon a review of our stock ledger maintained by our transfer agent and registrar, the following table sets forth the beneficial ownership of persons who owned more than five percent of our common stock following the execution and delivery of the Compromise and Settlement Agreement: Name Positions Held Shares Owned % - ---- -------------- ------------ --- David C. Merrell President and 746,592 55.6% 9005 Cobble Canyon Lane Director Sandy, Utah 84093 Todd D. Ross Secretary and -0- -0- 38 South 1650 West Director Cedar City, Utah 84720 Leonard W. Burningham, Esq. Stockholder 316,200 23.6% 455 East 500 South, Suite #205 Salt Lake City, Utah 84111 TOTALS 1,062,792 79.6% Item 2. Acquisition or Disposition of Assets. ------------------------------------- See Item 1. Item 3. Bankruptcy or Receivership. --------------------------- None, not applicable. Item 4. Changes in Registrant's Certifying Accountant. ---------------------------------------------- None, not applicable. Item 5. Other Events and Regulation FD Disclosure. ------------------------------------------ See the Press Release attached hereto and incorporated by reference. See Item 7. Item 6. Resignations of Registrant's Directors. --------------------------------------- Pursuant to the Compromise and Settlement Agreement, the persons who were then serving as our directors or executive officers had their election and designation as directors and executive officers declared void, and our former directors and executive officers, David C. Merrell and Todd D. Ross, were re- elected as our directors and executive officers for the remainder of their respective terms or until their successors are elected and qualified. Item 7. Financial Statements, Pro Forma Financial Information and Exhibits. --------- (a) None; not applicable. (b) None; not applicable. (c) Exhibits. 10.1 Compromise and Settlement Agreement 10.2 Civil Action Complaint 99 Press Release Item 8. Change in Fiscal Year. ---------------------- None; not applicable. Item 9. Regulation FD Disclosure. ------------------------- See Exhibit 99.2. SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. FIRST DELTAVISION, INC. DATED: 11/13/02 /s/ David C. Merrell -------- ------------------------- David C. Merrell President EX-10 3 compromiseagreement.txt COMPROMISE AND SETTLEMENT AGREEMENT THIS COMPROMISE AND SETTLEMENT AGREEMENT (the "Agreement") is made and entered into this __ day of October, 2002, by and between First Deltavision Inc., a Nevada corporation ("First Deltavision"); David C. Merrell, the former President of First Deltavision ("Merrell"); Kyomedix Corporation, a Delaware Corporation (hereby collectively referred to as "Kyomedix"); Atlantic Capital Partners Inc. and Health Sciences International Inc., the former sole stockholders of Kyomedix (the "Kyomedix Shareholders"); Michael Ivezic as a representative of Frankopan & Co., Inc., a financial consulting firm that negotiated the transaction between First Deltavision and Kyomedix ("Ivezic"); and Maryanne Beljo and David Coatsworth, as purchasers pursuant to certain Share Purchase Option Agreements ("Option Holders"); WITNESSETH: 1. Purpose The parties acknowledge that there presently exists a substantial, irreconcilable dispute among them, and without admitting or acknowledging the accuracy and truthfulness of the claims of any party, these parties have determined it to be in their mutual best interests to resolve any such dispute. Therefore, the purpose of this Agreement is to compromise and settle any and all claims or causes of action of any type or nature whatsoever or matters otherwise related to the dispute described in Section 2 hereinbelow, by, between and among the parties hereto and their respective successors, officers or agents, employees and stockholders. 2. Statement of Dispute 2.2 Pursuant to a share exchange agreement amongst First Deltavision, Kyomedix Corp. and all of its shareholders dated April 9, 2002 (the "Share Exchange Agreement"), First Deltavision purchased all issued and outstanding shares of Kyomedix stock, which purchase was effected by the issuance of 15,166,550 restricted common shares of First Deltavision to the Kyomedix shareholders on a share-for-share basis, thus affecting a "reverse merger," rendering Kyomedix a company whose stock was publicly traded and transferring control of the surviving entity to the principles of Kyomedix. 2.3 Article 2.5 of the Share Exchange Agreement, provides for the execution and delivery of a Promissory Note in the amount of $250,000.00 payable to David C. Merrell of First Deltavision. The Promissory Note was duly executed and delivered by Kyomedix, and the Kyomedix shareholders pledged substantially all of the shares of common stock of First Deltavision that they were to receive under the Share Exchange Agreement as security for the Promissory Note. Kyomedix has failed to make timely payments as agreed in the Share Exchange Agreement. 2.4 The KyoMedix shareholders delivered the Kyomedix Shares to First Deltavision upon closing as agreed in the Share Exchange Agreement, however First Deltavision failed or refused to deliver the First Deltavision shares to the KyoMedix shareholders in accordance with the terms of the Share Exchange Agreement. 2.5 Following the completion of the Share Exchange Agreement, First Deltavision was required to file reports with the Securities and Exchange Commission containing financial statements of First Deltavision and Kyomedix. Kyomedix failed to provide the financial statements needed to file such reports. By failing to file such reports, First Deltavision may lose its listing on the OTC Bulletin Board. 2.6 The following Share Purchase Option Agreements were executed pursuant to which certain stockholders of First Deltavision agreed to sell all or a portion of their shares of First Deltavision to the Option Holders for the aggregate consideration of $5,438.30; the closing of the Share Exchange Agreement was expected as part of the consideration for these options. Seller Shares Optioned Purchaser Jerry Peterson 8,608 Maryanne Beljo Todd D. Ross 11,108 Maryanne Beljo Lawrence O'Reilly 18,188 Maryanne Beljo Richard B. Scoville 3,944 David Coatsworth Raymond Wilson 21,000 David Coatsworth Jonathan Miller 20,000 David Coatsworth Mae Scoville 7,888 David Coatsworth Leonard W. Burningham 66,200 David Coatsworth Sheryl Ross 9,000 David Coatsworth Branden T. Burningham 9,000 David Coatsworth 2.6 First Deltavision and Merrell have filed a Civil Action against all of the parties except the Option Holders in the Third Judicial District Court in and for Salt Lake County, Utah, styled as Civil Action No. 020910071, a copy of which is attached hereto and incorporated herein as Exhibit A. 2.7 Kyomedix, the Kyomedix shareholders, Ivezic and the Option Holders deny the allegations of First Deltavision and Merrell contained herein or in Exhibit A. 3. Terms of Settlement 3.1 The Share Exchange Agreement will be rescinded and the 15,166,550 shares that First Deltavision claims were issued pursuant to that Agreement and are being held in escrow by Leonard W. Burningham will be returned to StockTrans, Inc., First Deltavision's transfer agent, for cancellation, save only for the retention of the four for one forward split by First Deltavision at its sole option. 3.2. The 186,648 pre-split shares of First Deltavision which were cancelled pursuant to Article 2.4 of the Share Exchange Agreement and which were owned by David C. Merrell shall be re-issued to Mr. Merrell to reflect post-split shares. 3.3 The Promissory Note in the amount of $250,000 payable to Mr. Merrell will be deemed null and void and the original Promissory Note will be returned to KyoMedix. 3.4 The adoption by First Deltavision of the Kyomedix Employee Stock Option Plan shall be voided and any options granted pursuant thereto will be withdrawn and void. 3.5 The Limited Indemnity Agreement executed by Mr. Merrell on the 9th day of April, 2002, will be deemed null and void. 3.6 The Certificate of Business: Fictitious Firm Name filed in the State of Nevada authorizing First Deltavision, Inc. to conduct business under the fictitious firm name of "KyoMedix, Inc." will be cancelled. 3.7 The Share Purchase Option Agreements, which by their terms, expired on the earlier of 30 days following the satisfaction of all conditions of such Option Agreements or 90 days from the date of execution, will be deemed null and void and the sum of $5,438.30 will be returned to the Option Holders or the person or persons who provided the funds for deposit into the trust account of Leonard W. Burningham, Esq., as the case may be. 3.8 The $10,000 .that was paid for legal fees in connection with the preparation and consummation of the Share Exchange Agreement will be either returned to the Company or applied against other legal work. 3.9 KyoMedix and the Kyomedix Shareholders shall indemnify and hold First Deltavision harmless from and against any and all liabilities that may have been incurred by KyoMedix since April 9, 2002, to the date hereof, while KyoMedix was under the control of any directors or executive officers who were the nominees of Kyomedix or its associates or the Kyomedix Shareholders or their associates. 3.10 The persons who are presently serving as directors or executive officers of First Deltavision shall have their election and designation as directors and executive officers of First Deltavision declared void, and the former directors and executive officers of First Deltavision, David C. Merrell and Todd D. Ross, shall be elected as the directors and executive officers for the remainder of their respective terms or until their successors are elected and qualified. 3.11 The parties hereto agree to release and waive any and all claims against the other parties hereto from and against any claims or causes brought by any successor, director, officer, agent, employee, stockholder or debtor, creditor or professional of any party who makes any claims or attempts to make any claims for any cause against any other party hereto based upon, related to or arising out of the Share Exchange Agreement, the dispute described herein, and the Civil Action described in Exhibit A, save and except for any claims against KyoMedix or the KyoMedix Shareholders pursuant to the indemnity described in Section 3.8 above. The waiver and release described herein may be raised in full estoppel and complete defence of any claim against any other party hereto that the releasing party may hereafter make or that anyone else may make on their behalf or that may be made by anyone claiming by, under or through such releasing party whether for contribution or indemnity or otherwise. 3.12 The Civil Action outlined in Exhibit A shall be dismissed by the plaintiffs forthwith, with prejudice as to all parties.3 The options outlined in Section 2.5 shall be null and void. 3.14 The parties agree that in the event of any default of this Compromise and Settlement Agreement by any party, the non-defaulting parties shall be entitled to recover reasonable attorney's fees and all costs incurred in enforcing the terms and provisions of this Agreement; further, each party designates the State of Nevada in the United States as the forum state for any legal proceeding respecting this proceeding, and each party consents to jurisdiction in the State of Nevada with respect to any such legal proceeding. 3.15 The parties agree that each party shall pay their own costs and expenses arising or related to (i) the consummation and rescission of the Share Exchange Agreement, (ii) the dispute and the Civil Action described in Exhibit A, and (iii) the negotiation of this Compromise and Settlement Agreement and any costs or expenses required to give effect to this Agreement. The parties further acknowledge and agree that they shall have no claim whatsoever for reimbursement or indemnity of any such costs and expenses from any other party hereto. 4. Change of Facts Each of the parties hereto acknowledges that to the best of his or its personal knowledge and belief, the facts and circumstances as known to each under which this Agreement has been executed and entered into are true, accurate and complete in all material respects, and each party further acknowledges that such facts or circumstances may in the future prove to be different, and each assumes the risk of any such facts or circumstances proving to be otherwise than those understood at the time of the execution of this Agreement. FIRST DELTAVISION, INC. Date: 11/11/02 By:/s/ David C. Merrell -------- ------------------------ David C. Merrell, President Date: 11/11/02 David C. Merrell -------- ------------------------ David C. Merrell, Individually KYOMEDIX CORPORATION Date: 11/07/02 By /s/ Peter Doederlein -------- ------------------------ Its____________________________ ATLANTIC CAPITAL PARTNERS, INC. Date: 11/11/02 By /s/ Anthony Smith -------- ------------------------ Its____________________________ HEALTH SCIENCES INTERNATIONAL, INC. Date: 11/07/02 By /s/ Peter Doederlein -------- ------------------------ Its____________________________ FRANKOPAN & CO., INC. Date: 11/07/02 By /s/ Michael Ivezic -------- ------------------------ Michael Ivezic Date: 11/07/02 Michael Ivezic -------- ------------------------ Michael Ivezic, Individually Date: 11/07/02 /s/ Michael Ivezic for Maryanne Beljo -------- ------------------------ Maryanne Beljo Date: 11/07/02 /s/ Michael Ivezic for David Coatsworth -------- ------------------------ David Coatsworth EXHIBIT A Larry G. Reed, # 2709 REED & WANGSGARD, LC 77 West 200 South, Suite 401 Salt Lake City, Utah 84101 Telephone: (801) 578-3510 Fax: (801) 578-3531 Attorneys for Plaintiffs IN THE THIRD JUDICIAL DISTRICT COURT OF SALT LAKE COUNTY STATE OF UTAH DAVID T. MERRELL, an individual, and FIRST DELTAVISION, INC., a Nevada corporation, Plaintiffs, vs. KYOMEDIX CORPORATION, formerly a Delaware corporation, n/k/a FIRST DELTAVISION, INC., a Nevada corporation; ATLANTIC CAPITAL PARTNERS, a Nevada limited partnership; HEALTH SCIENCES INTERNATIONAL, INC., an Ontario, Canada corporation; and MICHAEL IVEZIC, an individual; Defendants. COMPLAINT Civil No. _________________ Judge ____________________ Plaintiffs David T. Merrell ("Merrell") and First DeltaVision, Inc. ("DeltaVision-Nevada") allege: GENERAL ALLEGATIONS ------------------- Parties ------- 1. Merrell is a resident of Salt Lake County, State of Utah, and was, at all times pertinent to this action, the majority shareholder of DeltaVision-Nevada. 2. DeltaVision-Nevada is a Nevada corporation which now, following a merger, conducts business in Carson City, Nevada. 3. Kyomedix Corporation ("Kyomedix") was, prior to April 9, 2002, a Delaware corporation, which conducts business in the State of Nevada. 4. Atlantic Capital Partners, on information and belief, is a partnership with offices located in Scarborough, United Kingdom. 5. Health Sciences International, Inc. ("Health Sciences") is a Canadian corporation, with offices in Toronto, Ontario, Canada. 6. Michael Ivezic is an individual, who resides in Ontario, Canada. Jurisdiction and Venue ---------------------- 7. The Third Judicial District Court in and for Salt Lake County, State of Utah, has subject matter jurisdiction of the claims alleged below pursuant to the provisions of Section 78-3-4, Utah Code Ann. 8. Venue is properly laid before the Third Judicial District Court in and for Salt Lake County, State of Utah, pursuant to the provisions of Section 78-13-7, Utah Code Ann., in that none of the Defendants reside within the State of Utah, and Plaintiffs designate Salt Lake County, State of Utah, as their choice of venue. 9. This Court possesses in personam jurisdiction of each Defendant pursuant to the provisions of Section 78-27-24(1), Utah Code Ann., in that the claims alleged below arise from the transaction of business in the State of Utah, specifically the completion of an exchange of stock, the negotiation of a share exchange agreement, and the communication of certain false representations to Plaintiffs within the State of Utah. General Allegations of Fact --------------------------- 10. Prior to April 9, 2002, DeltaVision-Nevada was a Nevada corporation whose stock was publicly traded. 11. Prior to April 9, 2002, Kyomedix was a Delaware corporation, whose stock was not publicly traded. 12. Atlantic, Health Sciences, both then shareholders of Kyomedix, and Kyomedix, through their representatives, Michael Ivezic, approached DeltaVision-Nevada and its primary shareholder and President, Merrell, and proposed that the two corporations engage in a transaction known as a "reverse merger". 13. Ivezic, on behalf of the other Defendants, represented to DeltaVision-Nevada and Merrell that Kyomedix had "U.S. $2 million financing in place, that will fund further product development and new product growth". 14. Ivezic provided DeltaVision-Nevada and Merrell with a copy of a Kyomedix Business Plan and the resume's of persons represented to be principals or employees of Kyomedix. Certain statements in the Business Plan were false. 15. Based on these representations and a review of the resume's and Business Plan of Kyomedix, DeltaVision-Nevada and Merrell were induced to enter into a Share Exchange Agreement, dated April 9, 2002, a copy of which is attached hereto as Exhibit "A". 16. Through that Share Exchange Agreement, DeltaVision-Nevada purchased all issued and outstanding shares of Kyomedix stock, which purchase was effected by the issuance of 15,166,550 restricted common shares of DeltaVision-Nevada to the Kyomedix shareholders on a share-for-share basis, thus affecting a "reverse merger", rendering Kyomedix a company whose stock was publicly traded and transferring control of the surviving entity to the principals of Kyomedix. FIRST CAUSE OF ACTION --------------------- (Fraud) 17. Plaintiffs, by this reference, hereby incorporate the allegations of paragraphs nos. 1 through 16, above, as if fully set forth herein. 18. The representations set forth in paragraphs nos. 15 and 16, above, concerned presently existing material facts. 19. Those representations were false. 20. Each Defendant knew those representations to be false at the time they were made, or those representations were made recklessly, and Defendants knew that they had insufficient knowledge upon which to base those representations. 21. Those representations were made for the purpose of inducing DeltaVision-Nevada and Merrell to act upon them and to agree to enter into the Share Exchange Agreement. 22. DeltaVision-Nevada and Merrell each acted reasonably and in ignorance of the falsity of those representations and did, in fact, rely upon them. 23. DeltaVision-Nevada and Merrell were thereby induced to act and engage in a reverse merger with Kyomedix through the Shareholder Agreement to their injury and damage. 24. By virtue of those fraudulent representations, DeltaVision-Nevada and Merrell have been damaged in the approximate amount of $___________________, the exact amount to be established at the time of trial. 25. The conduct of Defendants, as set forth in this cause of action, was both knowing and intentional, and was accomplished in complete disregard of the rights of DeltaVision-Nevada and Merrell. Plaintiffs are, therefore, entitled to recover punitive damages in an amount deemed just by this Court. SECOND CAUSE OF ACTION ---------------------- (Rescission) 26. Plaintiffs, by this reference, hereby incorporate the allegations of paragraphs nos. 1 through 25, above, as if fully set forth herein. 27. The representations set forth in paragraphs nos. 15 and 16 above, concerned presently existing material facts. 28. Those representations were false. 29. Each Defendant knew those representations to be false at the time they were made, or those representations were made recklessly, and Defendants knew that they had insufficient knowledge upon which to base those representations. 30. Those representations were made for the purpose of inducing DeltaVision-Nevada and Merrell to act upon them and to agree to enter into the Share Exchange Agreement. 31. DeltaVision-Nevada and Merrell each acted reasonably and in ignorance of the falsity of those representations and did, in fact, rely upon them. 32. DeltaVision-Nevada and Merrell were thereby fraudulently induced to act and engage in a reverse merger with Kyomedix through the Shareholder Agreement to their injury and damage. 33. By virtue of this fraudulent inducement, in equity, the Share Exchange Agreement must be rescinded and all shares of stock transferred pursuant to that Agreement must be returned to Plaintiffs. 34. By virtue of the foregoing, this Court should enter a Decree of Rescission, directing Defendants, and each of them, to execute such documents and to perform such actions as are necessary to rescind the Share Exchange Agreement. THIRD CAUSE OF ACTION --------------------- (Conversion) 35. Plaintiffs, by this reference, hereby incorporate the allegations of paragraphs nos. 1 through 34, above, as if fully set forth herein. 36. Defendants acquired the issued and outstanding shares of DeltaVision-Nevada through fraud, as alleged above. 37. Thus, Defendants have no right to the possession or ownership of those shares of stock issued by DeltaVision-Nevada. 38. Plaintiffs have a present right to ownership and possession of the shares of the DeltaVision-Nevada stock fraudulently obtained by Defendants. 39. Defendants have a knowledge of that right to immediate possession by Plaintiffs. 40. Defendants have, thus, converted, to their own use, the shares of stock issued by DeltaVision-Nevada now possessed by them. 41. By reason of that conversion, Plaintiffs have suffered and will continue to suffer, damages in the amount of the highest trading value of DeltaVision-Nevada stock from the time of the conversion through the time of trial. FOURTH CAUSE OF ACTION ---------------------- (Replevin) 42. Plaintiffs, by this reference, hereby incorporate the allegations of paragraphs nos. 1 through 41, above, as if fully set forth herein. 43. The shares of stock at issue, i.e., the shares of stock issued by DeltaVision-Nevada and converted by Defendants to their own use, are the property of Plaintiffs. 44. Those shares of stock and the certificates representing those shares of stock are wrongfully detained by Defendants. 45. Those shares of stock have not been taken for tax, assessment or a fine pursuant to a statute, nor have they been seized under an execution or an attachment against the property of Plaintiffs. 46. Plaintiffs are, thus, entitled to the issuance of a Writ of Replevin, directing an appropriate officer to seize and take those securities and the share certificates representing those securities and any proceeds of the sale of those securities, and to return the same to Plaintiffs. FIFTH CAUSE OF ACTION --------------------- (Violation of Section 61-1-1, Utah Code Ann.) 47. Plaintiffs, by this reference, hereby incorporate the allegations of paragraphs nos. 1 through 46, above, as if fully set forth herein. 48. This claim arises under Section 61-1-1, Utah Code Ann. 49. Defendants communicated false and misleading information which constitutes an untrue statement of a material fact concerning those matters set forth in paragraphs nos. 15 and 16 above, for the sole purpose of inducing Plaintiffs to sell DeltaVision-Nevada stock to Defendants and to purchase Kyomedix stock. 50. As a direct result of the unlawful conduct of Defendants, as alleged above, Plaintiffs were thereby induced to sell DeltaVision-Nevada stock to Defendants and to purchase Kyomedix stock from them causing damage in an amount to be established at the time of trial. SIXTH CAUSE OF ACTION --------------------- (Breach of Agreement) 51. Plaintiffs, by this reference, hereby incorporate the allegations of paragraphs nos. 1 through 50, above, as if fully set forth herein. 52. Article 2.5 of the Share Exchange Agreement, provides for the execution and delivery to Merrell of a Promissory Note in the face amount of $250,000.00 and the payment of that amount. A true and correct copy of that Promissory Note, executed pursuant to the Share Exchange Agreement, is attached hereto as Exhibit "B". 53. Kyomedix, Atlantic and Health Sciences have each failed to make payment as required by that Promissory Note. 54. The breach of the requirements of the Promissory Note and of Article 2.5 of the Share Exchange Agreement has caused Merrell to suffer damages in the amount of $250,000.00, plus accrued interest. 55. Article 11.11 of the Share Exchange Agreement provides, as follows: In the event of default, the prevailing party shall be entitled to reasonable attorneys fees and related costs of court. 56. Atlantic, Health Sciences and Kyomedix have defaulted in performing the requirements of Article 2.5. Thus, Merrell is entitled to recover his attorneys' fees and costs of court incurred in this matter. SEVENTH CAUSE OF ACTION ----------------------- (Foreclosure of Security Interest) 57. Plaintiffs, by this reference, hereby incorporate the allegations of paragraphs nos. 1 through 56, above, as if fully set forth herein. 58. The Promissory Note, which is attached as Exhibit "B", hereto, grants to Merrell a Security Interest in 13,916,000 post-dividend shares of DeltaVision-Nevada. 59. The certificates representing those shares of DeltaVision-Nevada stock, pledged as security for payment of the Promissory Note, are held, in escrow, by Leonard W. Burningham, an attorney licensed to practice law in the State of Utah. 60. The Court should issue a Decree of Foreclosure directing Leonard W. Burningham to deliver those share certificates to Merrell. 61. Merrell is entitled to recover his attorneys' fees and costs of court incurred in this matter. WHEREFORE, DeltaVision-Nevada and David C. Merrell pray judgment as follows: 1. On the First Cause of Action, for damages in an amount to be established at the time of trial, plus punitive damages in an amount deemed just by this Court; 2. On the Second Cause of Action, for the Court to enter a Decree of Rescission, directing Defendants, and each of them, to execute such documents and to perform such actions as are necessary to rescind the Share Exchange Agreement; 3. On the Third Cause of Action, for damages in the amount of the highest trading value of DeltaVision-Nevada stock from the time of the conversion through the time of trial, plus punitive damages; 4. On the Fourth Cause of Action, for the issuance of a Writ of Replevin, directing an appropriate officer to seize and take those securities and the share certificates representing those securities and any proceeds of the sale of those securities, and to return the same to Plaintiffs. 5. On the Fifth Cause of Action, for damages in an amount to be established at the time of trial, plus punitive damages; 6. On the Sixth Cause of Action, for judgment in the amount of $250,000.00, plus attorneys' fees and costs of court incurred in this matter; 7. On the Seventh Cause of Action, for the issuance of an Order directing Leonard W. Burningham to release certain share certificates to Merrell, plus attorneys' fees and costs of Court; 8. For Plaintiff's attorneys' fees and costs of Court incurred herein pursuant to Article 11.11 of the Share Exchange Agreement and pursuant to the third paragraph of the Promissory Note; and 9. For such other and further relief as the Court deems just. Dated this day of September, 2002. REED & WANGSGARD, LC ------------------------ Larry G. Reed Attorneys for Plaintiffs Plaintiff's Address: 9005 Cobble Canyon Lane Sandy, Utah 84093 EX-99 4 pressrelease.txt FIRST DELTAVISION, INC. ANNOUNCES RECISSION OF SHARE EXCHANGE AGREEMENT. SALT LAKE CITY, UTAH-(BUSINESS WIRE)-November 12, 2002-First Deltavision, Inc. (OTCBB Symbol: "KMDX"), announced today the recission of the Share Exchange Agreement (the "Kyomedix Agreement") with Kyomedix Corporation, a Delaware corporation, that was reported in its 8-K Current Report dated April 9, 2002. David C. Merrell, President, stated "The recision places the parties in the same positions they were in prior to the completion of the Kyomedix Agreement, except that we retained the four for one forward split of our outstanding shares." The terms of the recision are contained in the Form 8-KA Current Report of First Deltavision dated April 9, 2002, which was filed with the Securities and Exchange Commission on November 13, 2002. For further information please contact: David C. Merrell First Deltavision, Inc. 9005 Cobble Canyon Lane Sandy, Utah 84093 Telephone: (801) 942-0555 -----END PRIVACY-ENHANCED MESSAGE-----